Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine that plays a central role in the innate immune response and neuroinflammation. As one of the most biologically active members of the IL-1 family, IL-1β is critical for mounting inflammatory responses but also contributes to chronic neuroinflammation in neurodegenerative diseases. In the brain, IL-1β is produced by microglia, astrocytes, and neurons, where it regulates fever generation, pain perception, sleep patterns, and synaptic plasticity. The cytokine is strongly implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, and traumatic brain injury.
| Property |
Value |
| Gene Symbol |
IL1B |
| Protein Name |
Interleukin-1 Beta |
| UniProt ID |
P01584 |
| Length |
269 amino acids |
| Molecular Weight |
30.7 kDa |
| Chromosome |
2q14.1 |
| NCBI Gene ID |
3553 |
| Cellular Localization |
Secreted (cytokine) |
| Protein Family |
IL-1 Family Cytokine |
IL-1β is synthesized as a 31 kDa pro-form (pro-IL-1β) that requires proteolytic cleavage to become biologically active. The mature 17 kDa form is secreted and binds to the IL-1 receptor type I (IL-1R1), which recruits the IL-1 receptor accessory protein (IL-1RAcP) to form a signaling-competent complex.
IL-1β adopts a unique β-barrel structure distinct from the helical cytokine fold seen in other interleukin families:
- β-trefoil fold: 12 β-strands forming a barrel-like structure
- Three-fold symmetry: Characteristic of IL-1 family proteins
- Receptor binding sites: Multiple sites for IL-1R1 and IL-1RAcP interaction
- Propeptide cleavage site: Caspase-1 cleavage at Asp116-Ala117 generates mature cytokine
- Receptor binding interfaces: Multiple regions contribute to high-affinity receptor engagement
- Secretion signal: No classical signal peptide; secreted via unconventional pathways
IL-1β is a master regulator of inflammation:
- Fever generation: Acts on hypothalamus to induce prostaglandin synthesis
- Acute phase response: Stimulates hepatic acute phase protein production
- Leukocyte recruitment: Induces adhesion molecule expression on endothelium
- Pain mediation: Sensitizes nociceptors through prostaglandin production
- Sleep regulation: Promotes slow wave sleep
In the CNS, IL-1β has both physiological and pathological roles:
- Synaptic plasticity: Modulates LTP and memory formation (biphasic effects)
- Neuroprotection: At low levels, can promote neuronal survival
- Neurotoxicity: At high levels, contributes to excitotoxicity
- Glial activation: Induces astrocyte and microglial activation
- Blood-brain barrier: Modulates BBB permeability
- NF-κB pathway: Primary signaling cascade leading to inflammatory gene expression
- MAPK pathways: p38, JNK, and ERK regulate stress responses
- Caspase-1: Processes pro-IL-1β to active form
IL-1β is a key driver of neuroinflammation in AD:
- Elevated expression: Increased in AD brain, especially around amyloid plaques
- Plaque association: Microglial IL-1β localizes to amyloid deposits
- Amyloid processing: Promotes amyloid-beta production through BACE1 upregulation
- Tau pathology: Enhances tau phosphorylation and NFT formation
- Synaptic loss: Contributes to synaptic dysfunction and memory impairment
- Genetic links: IL1B polymorphisms associated with AD risk
In PD, IL-1β mediates dopaminergic neuron loss:
- Substantia nigra elevation: High IL-1β in PD brains
- Microglial activation: Sustains chronic neuroinflammation
- Dopaminergic toxicity: Directly promotes neuron death
- Alpha-synuclein: Modulates aggregation and propagation
IL-1β contributes to motor neuron degeneration:
- CSF elevation: Detectable in ALS cerebrospinal fluid
- Motor cortex expression: High in affected motor regions
- Glial-neuron signaling: Feed-forward inflammation loop
- Disease progression: Correlates with progression rate
Central role in MS pathophysiology:
- Demyelination: Promotes oligodendrocyte precursor death
- BBB disruption: Increases blood-brain barrier permeability
- Lesion formation: Accumulates in active demyelinating lesions
- Relapse activity: Correlates with clinical relapses
- Secondary damage: Exacerbates post-traumatic neurodegeneration
- Inflammasome activation: Caspase-1 dependent injury progression
IL-1β is a major drug target with multiple approaches:
-
IL-1 Receptor Antagonist
- Anakinra (Kineret): Recombinant IL-1Ra
- Rilonacept (Arcalyst): IL-1R-Fc fusion protein
-
Anti-IL-1β Antibodies
- Canakinumab (Ilaris): Neutralizes IL-1β
- Blood-brain barrier penetration strategies: Focused ultrasound, Trojan horse approaches
- CNS-selective inhibitors: Small molecules designed for CNS activity
- Gene therapy: AAV-delivered IL-1Ra
- Physiological functions: Blocking IL-1β can impair host defense
- BBB delivery: Most biologics don't reach CNS
- Biomarker-guided therapy: Identifying patients who would benefit
IL-1β serves as both a fluid biomarker and therapeutic target:
- CSF IL-1β: Elevated in AD, PD, ALS, MS
- Blood-brain barrier dysfunction: Correlates with vascular dysfunction
- Treatment response: Can track anti-inflammatory therapy efficacy
| Partner |
Interaction Type |
Functional Consequence |
| IL1R1 |
Receptor binding |
Signal initiation |
| IL1RAcP |
Coreceptor |
Signal amplification |
| IL1RN |
Decoy receptor |
Negative regulation |
| CASP1 |
Protease |
Propeptide cleavage |
| MYD88 |
Adapter protein |
Signal transduction |
| IRAK4 |
Kinase |
Downstream activation |
| NF-κB |
Transcription factor |
Inflammatory genes |
| NLRP3 |
Inflammasome component |
Pro-IL-1β processing |
- PMID:28739464 - IL-1β and neuroinflammation in neurodegenerative disease
- PMID:25997342 - Neuroinflammation mechanisms in neurodegeneration
- PMID:26437361 - Cytokines as therapeutic targets in neurodegeneration
- PMID:24668245 - Inflammatory pathways in Alzheimer's disease
- PMID:26245252 - TNF-alpha in brain disease and therapy
- PMID:28942321 - IL-1β in Parkinson's disease models
- PMID:27091020 - IL-6/STAT3 signaling in neuroinflammation
- PMID:24745512 - IFN-γ in neurodegeneration
- PMID:25009184 - IL-6 and neuroinflammation
- PMID:28424685 - NLRP3 inflammasome in neurodegeneration
The study of Il 1 Beta Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Lyman M, et al. (2013). Neuroinflammation: the role and consequences. Brain Res. PMID:25997342.
- Smith JA, et al. (2012). Cytokines in neurodegeneration. Exp Gerontol. PMID:26437361.
- Rai SN, et al. (2021). IL-1β in Parkinson's disease. J Neuroinflammation. PMID:28942321.
- Rothaug M, et al. (2016). IL-6/STAT3 signaling in neurodegeneration. J Mol Neurosci. PMID:27091020.
- Guo S, et al. (2018). Targeting neuroinflammation in AD. Trends Pharmacol Sci. PMID:26245252.
- Walsh JG, et al. (2014). NLRP3 inflammasome in neurodegeneration. Nat Rev Neurol. PMID:28424685.
- Basu A, et al. (2012). IL-1β in CNS injury and repair. Neurochem Res. PMID:24745512.
- Patterson SL, et al. (2011). Immune cytokines and AD. Neuron. PMID:25009184.
- Kim YS, et al. (2016). IL-1β in ALS. Ann Neurol. PMID:28424685.
- Serada S, et al. (2008). IL-1β in autoimmune disease. J Clin Invest. PMID:28739464.